An antibody–drug conjugate (MK-2140; VLS-101) consisting of a humanized anti-ROR1 monoclonal antibody linked via a cleavable linker to the cytotoxic payload monomethyl auristatin E (MMAE), a microtubule inhibitor; targets ROR1-expressing tumor cells to deliver MMAE intracellularly.
Humanized anti-ROR1 monoclonal antibody linked via a cleavable linker to monomethyl auristatin E (MMAE). After binding ROR1 on tumor cells and internalization, the linker is cleaved to release MMAE, which inhibits microtubule polymerization, leading to mitotic arrest and apoptosis of ROR1-expressing cancer cells.
An anti-ROR1 antibody–drug conjugate binds ROR1, is internalized, and releases MMAE intracellularly, inhibiting microtubule polymerization and causing mitotic arrest and apoptosis of ROR1-expressing cells.
Autologous, gene-modified T cells engineered to express a chimeric antigen receptor targeting B-cell maturation antigen (BCMA/TNFRSF17), enabling TCR-independent recognition and cytolysis of BCMA-positive myeloma cells; administered via IV infusion.
Autologous, gene-modified T cells expressing a chimeric antigen receptor bind BCMA on myeloma cells, triggering TCR-independent activation (CD3zeta/costimulatory signaling), proliferation, cytokine release, and cytolytic killing via perforin/granzyme, resulting in depletion of BCMA-positive plasma cells.
CAR binding to BCMA activates the engineered T cells (CD3ζ/costimulatory signaling), leading to perforin/granzyme-mediated cytolysis of BCMA-positive cells (and potentially Fas/FasL apoptosis).
Chimeric anti-CD20 monoclonal antibody that depletes B cells via ADCC, CDC, and apoptosis.
Chimeric anti-CD20 monoclonal antibody that binds CD20 on B lymphocytes and depletes CD20-positive cells via antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, and induction of apoptosis.
Anti-CD20 antibody binds CD20 on B cells and triggers Fc-mediated ADCC by NK/macrophages, complement-dependent cytotoxicity (CDC), and can induce apoptosis.
Rituximab is a chimeric anti-CD20 IgG1 monoclonal antibody that depletes CD20-positive B cells via antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, and apoptosis.
Chimeric anti-CD20 IgG1 monoclonal antibody that binds CD20 on B lymphocytes and depletes CD20-positive cells via antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, and induction of apoptosis.
Binds CD20 on B cells and engages immune effectors via its Fc to induce ADCC and complement-dependent cytotoxicity; CD20 ligation can also trigger apoptosis.
A PTK7-targeted antibody–drug conjugate administered intravenously; the monoclonal antibody binds PTK7 on tumor cells, is internalized, and releases a cytotoxic payload to induce tumor cell death in PTK7-expressing solid tumors.
PTK7-targeted monoclonal antibody linked to a cytotoxic payload; after binding PTK7 on tumor cells, the ADC is internalized and releases its payload intracellularly, causing cytotoxicity and death of PTK7-expressing tumor cells.
ADC binds PTK7 on tumor cells, is internalized, and releases an intracellular cytotoxic payload that kills the PTK7-expressing cell.